Results 191 to 200 of about 6,111,093 (245)
Stress-induced cardiomyopathy with electrocardiographic ST-segment elevation in a patient with pneumothorax. [PDF]
World J Emerg Med, 2020 Cho JW, Bae CH.
europepmc +1 more source
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys +14 more
wiley +1 more source
An unusual cause of polymorphic ventricular tachycardia: Acquired long QT syndrome from atypical variant of stress-induced cardiomyopathy. [PDF]
SAGE Open Med Case Rep, 2020 Alfarih M +4 more
europepmc +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann +7 more
wiley +1 more source
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
British Journal of Pharmacology, EarlyView.Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source
Dietary melatonin and its benefits on cardiovascular disease
British Journal of Pharmacology, EarlyView.Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane +2 more
wiley +1 more source
Association of Endocrine Conditions With Takotsubo Cardiomyopathy: A Comprehensive Review
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 Sonali Gupta +5 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan +13 more
wiley +1 more source